Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1990 4
1991 2
1992 7
1993 6
1994 4
1995 4
1996 1
1997 4
1998 4
2001 3
2002 11
2003 9
2004 14
2005 26
2006 12
2007 20
2008 18
2009 24
2010 43
2011 41
2012 30
2013 38
2014 39
2015 61
2016 69
2017 94
2018 136
2019 135
2020 142
2021 200
2022 175
2023 218
2024 133

Text availability

Article attribute

Article type

Publication date

Search Results

1,564 results

Results by year

Filters applied: . Clear all
Page 1
Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH).
Peng Z, Fan W, Zhu B, Wang G, Sun J, Xiao C, Huang F, Tang R, Cheng Y, Huang Z, Liang Y, Fan H, Qiao L, Li F, Zhuang W, Peng B, Wang J, Li J, Kuang M. Peng Z, et al. Among authors: zhuang w. J Clin Oncol. 2023 Jan 1;41(1):117-127. doi: 10.1200/JCO.22.00392. Epub 2022 Aug 3. J Clin Oncol. 2023. PMID: 35921605 Clinical Trial.
Signaling pathways in cancer metabolism: mechanisms and therapeutic targets.
You M, Xie Z, Zhang N, Zhang Y, Xiao D, Liu S, Zhuang W, Li L, Tao Y. You M, et al. Among authors: zhuang w. Signal Transduct Target Ther. 2023 May 10;8(1):196. doi: 10.1038/s41392-023-01442-3. Signal Transduct Target Ther. 2023. PMID: 37164974 Free PMC article. Review.
First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial.
Song Y, Zhang B, Xin D, Kou X, Tan Z, Zhang S, Sun M, Zhou J, Fan M, Zhang M, Song Y, Li S, Yuan Y, Zhuang W, Zhang J, Zhang L, Jiang H, Gu K, Ye H, Ke Y, Li J, Wang Q, Zhu J, Huang J; ASTRUM-007 investigators. Song Y, et al. Among authors: zhuang w. Nat Med. 2023 Feb;29(2):473-482. doi: 10.1038/s41591-022-02179-2. Epub 2023 Feb 2. Nat Med. 2023. PMID: 36732627 Free PMC article. Clinical Trial.
CTNNB1 in neurodevelopmental disorders.
Zhuang W, Ye T, Wang W, Song W, Tan T. Zhuang W, et al. Front Psychiatry. 2023 Mar 16;14:1143328. doi: 10.3389/fpsyt.2023.1143328. eCollection 2023. Front Psychiatry. 2023. PMID: 37009120 Free PMC article. Review.
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study.
Lu S, Zhou J, Jian H, Wu L, Cheng Y, Fan Y, Fang J, Chen G, Zhang Z, Lv D, Jiang L, Wu R, Jin X, Zhang X, Zhang J, Xie C, Sun G, Huang D, Cui J, Guo R, Han Z, Chen Z, Liang J, Zhuang W, Hu X, Zang A, Zhang Y, Cang S, Lan Y, Chen X, Liu L, Li X, Chen J, Ma R, Guo Y, Sun P, Tian P, Pan Y, Liu Z, Cao P, Ding L, Wang Y, Yuan X, Wu P. Lu S, et al. Among authors: zhuang w. Lancet Respir Med. 2023 Oct;11(10):905-915. doi: 10.1016/S2213-2600(23)00183-2. Epub 2023 May 24. Lancet Respir Med. 2023. PMID: 37244266 Clinical Trial.
1,564 results